D
Sagimet Biosciences Inc. SGMT
$5.15 -$0.10-1.91% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$5.15
Volume
569
Avg Vol (90D)
642,341
Market Cap
$167.49M
Dividend & Yield
--
52-Week Range
$1.73 - $11.41
P/E (TTM)
--
EPS (TTM)
-$1.79
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Sagimet Biosciences (NASDAQ:SGMT) CEO David Happel Sells 12,101 Shares of Stock
2/13/2026 - Ticker Report
Sagimet Biosciences (NASDAQ:SGMT) CEO Sells $64,861.36 in Stock
2/13/2026 - MarketBeat
David Happel Sells 12,101 Shares of Sagimet Biosciences (NASDAQ:SGMT) Stock
2/12/2026 - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Recommendation of "Moderate Buy" from Brokerages
2/11/2026 - MarketBeat
Assessing Sagimet Biosciences (SGMT) Valuation After Positive Denifanstat Phase 3 Acne Trial Results
2/5/2026 - Simply Wall St
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
2/5/2026 - Globe Newswire
Why Sagimet Biosciences (SGMT) Is Up 7.7% After Denifanstat's Phase 3 Acne Success And What's Next
2/4/2026 - Simply Wall St
HC Wainwright Reaffirms Buy Rating for Sagimet Biosciences (NASDAQ:SGMT)
2/3/2026 - Zolmax
Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright
2/3/2026 - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from Analysts at Guggenheim
2/3/2026 - MarketBeat
Sagimet Biosciences initiated with bullish view at Guggenheim, here's why
2/3/2026 - The Fly
Sagimet Biosciences initiated with bullish view at Guggenheim, here's why
2/3/2026 - The Fly
Sagimet Biosciences price target raised by $8 at Clear Street, here's why
2/3/2026 - The Fly
Sagimet Biosciences price target raised by $8 at Clear Street, here's why
2/3/2026 - The Fly
Sagimet Biosciences announces license partner Ascletis issues results for ASC40
2/2/2026 - The Fly
Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
2/2/2026 - Globe Newswire
Sagimet Biosciences (SGMT) Falls as Partner Reports Trial Data
1/29/2026 - GuruFocus
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
1/29/2026 - PR Newswire
Sagimet Biosciences (SGMT) Receives New Analyst Rating from Barclays SGMT Stock News
1/28/2026 - GuruFocus
Sagimet Biosciences initiated with neutral view at Barclays, here's why
1/27/2026 - The Fly
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
1/27/2026 - Globe Newswire
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by Analysts
1/17/2026 - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Shares Down 0.5% - Here's Why
1/14/2026 - MarketBeat
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely
1/12/2026 - Simply Wall St
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
1/8/2026 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$64.32M
Net Income (TTM)
-$57.67M
Balance Sheet
Total Assets (Q)
$128.40M
Total Debt (Q)
$115.00K
Total Liabilities (Q)
$9.15M
Book Value Per Share (Q)
$3.67
Cash Flow
Cash from Operations (TTM)
-$44.84M
Cash from Investing (TTM)
$48.00K
Cash from Financing (TTM)
$275.00K
Net Change in Cash (TTM)
-$44.52M
Filings
Filing Date
Thursday, November 13, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
2.84
7-Day Total Return
-15.30%
30-Day Total Return
-13.01%
60-Day Total Return
-34.06%
90-Day Total Return
-29.55%
Year to Date Total Return
-14.02%
1-Year Total Return
17.05%
2-Year Total Return
-30.59%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $1.73
52-week High
Jul 25, 2025 - $11.41
Valuation
Market Cap
$167.49M - Micro Cap
Enterprise Value
$42.10M
Price/Sales (TTM)
--
Price/Book (Q)
1.40
Dividends and Shares
Shares Outstanding
32.46M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.sagimet.com
Phone Number
650 561 8600
Address
155 Bovet Road
San Mateo, CA 94402
Country
United States
Year Founded
2006
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from... more
NASDAQ 02/12/2026 4:00PM Eastern Quotes delayed